Akinion Pharmaceuticals initiates Phase I/II clinical trial with AKN-028
(Thomson Reuters ONE) -
STOCKHOLM, SWEDEN - January 9, 2012. Akinion Pharmaceuticals AB, a Karolinska
Development AB portfolio company, announced today that the first patient has
been dosed with AKN-028 in a Phase I/II clinical trial in acute myeloid leukemia
(AML).
The Phase I/II trial with AKN-028 is a two-part international multi-center study
in patients with AML. The first part is a dose-escalating study where AKN-028 is
administered orally twice a day, until the maximum tolerated dose is
established. The second part is a proof-of-concept study where approximately 20
patients will be treated. The trial will assess the safety, tolerability,
pharmacokinetics and anti-leukemic effect of AKN-028.
About 42 000 new cases of AML are diagnosed in the US, EU and Japan each year
and deaths from AML total about 30 000. The 5-year survival rate is only 34
percent for adults aged below 65 and 4 percent for those aged 65 or older.
Current treatments include chemotherapy and bone marrow transplantation, but no
targeted treatments are approved yet. AKN-028 is a targeted oral small molecule
FLT3 and cKIT kinase inhibitor with a unique differentiating efficacy against
leukemic cells resistant to current therapies.
Dr. Carl Harald Janson, CEO, Akinion Pharmaceuticals:
"The recruitment of the first patient to the Phase I/II clinical trial is an
important milestone for Akinion Pharmaceuticals. In its preclinical studies,
AKN-028 has shown excellent efficacy and features which we believe will be of
great value to patients, and which differentiate AKN-028 positively from other
drugs on the market or in development for this disease."
Dr. Torbjörn Bjerke, CEO, Karolinska Development:
"We are very pleased that Akinion Pharmaceuticals has initiated this important
clinical trial, marking the progression from preclinical studies to the clinical
development stage. There is a high medical need in this patient population and a
positive outcome from this clinical trial will be of great importance both for
patients and for Karolinska Development."
For further information, please contact:
Carl Harald Janson, CEO Akinion Pharmaceuticals AB
Phone: +46 (0) 70 226 91 52, e-mail: carlharald.janson(at)akinion.com
Torbjörn Bjerke, CEO Karolinska Development AB
Phone: +46 (0) 72 744 41 23, e-mail: torbjorn.bjerke(at)karolinskadevelopment.com
TO THE EDITORS
About Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB is a Swedish biotech company founded in 2009. The
company is developing kinase receptor inhibitors for treatment of acute myeloid
leukemia. Akinion Pharmaceuticals is part of the Karolinska Development
portfolio of companies.www.akinion.com
About Karolinska Development AB
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class science into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP innovations
to the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out-licensing of
products. An exclusive deal flow agreement with Karolinska Institutet
Innovations AB, along with other cooperation agreements with leading Nordic
universities, delivers a continuous flow of innovations. Today, the portfolio
consists of 33 projects, of which 13 are in clinical development. For more
information, please visitwww.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be
required to disclose the information provided herein pursuant to the Securities
Markets Act.
Press release as PDF:
http://hugin.info/143071/R/1575834/490896.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
[HUG#1575834]
Unternehmensinformation / Kurzprofil:
Datum: 09.01.2012 - 08:31 Uhr
Sprache: Deutsch
News-ID 101935
Anzahl Zeichen: 4745
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Akinion Pharmaceuticals initiates Phase I/II clinical trial with AKN-028"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
